Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also includes comprehensive business updates, R&D activities, production capacity expansions, and social responsibility initiatives. The length of the document (11,473 characters) and the presence of substantive financial data and analysis confirm it is a financial report rather than a brief announcement or certification. The content matches the characteristics of an Interim / Quarterly Report, which covers a period shorter than a full fiscal year and includes actual financial statements and business analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 39th meeting of the 4th Board of Directors of the company. It specifically mentions the approval of the 2022 half-year report and a special report on the use of raised funds. However, the document itself does not contain the actual financial statements or detailed report content; instead, it refers readers to the full reports published on the official disclosure website. The document length is short (979 characters) and serves as a notice of the board meeting decisions and report approvals rather than the reports themselves. According to the 'Menu vs Meal' rule, this is an announcement about reports, not the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2022-08-25 Chinese
2022年半年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (463 characters) indicating that the company has approved its 2022 half-year report and that the full report and summary will be published on a specified website on August 26, 2022. It does not contain the actual financial data or the report itself but rather informs investors about the upcoming publication of the half-year report. According to the 'MENU VS MEAL' rule, such a brief notice about the report's availability is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2022-08-25 Chinese
独立董事关于公司第四届董事会第三十九次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent director's opinion on matters related to the company's 2022 half-year report, including external guarantees, related party transactions, and the use of raised funds. It references the half-year period (January 1 to June 30, 2022) and provides an independent opinion on the company's half-year report and related special reports. The document is a formal opinion letter from independent directors rather than the half-year report itself. It does not contain actual financial statements or substantive financial data but rather an attestation and review of certain aspects of the half-year report. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports and related opinions, excluding full annual or interim reports. H1 2022
2022-08-25 Chinese
2022年股票期权激励计划预留授予激励对象名单
Capital/Financing Update Classification · 95% confidence The document is titled as a list of reserved stock option incentive plan recipients for the year 2022, detailing the allocation of stock options to directors, senior management, and core personnel. It is a specific announcement related to stock option incentives rather than a full financial report, earnings release, or management discussion. The document length is short (1418 characters) and it primarily lists names and option quantities without financial statements or analysis. This fits best under a category related to capital or financing updates, specifically stock option plans which affect capital structure and incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-08-24 Chinese
独立董事关于第四届董事会第三十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting resolution related to the company's 2022 stock option incentive plan. It references compliance with regulatory rules and company bylaws, and it is a formal opinion on a board decision rather than a full report or announcement of financial results. The document length is short (1096 characters), and it does not contain financial statements or detailed financial data. It is not an announcement of voting results but an independent opinion on a board matter. This fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2022-08-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.